Key result
VEGF-D promotes lung endothelial barrier integrity and capillary homeostasis in acute lung injury.
Why the study?
The specific local cell-cell crosstalk signals that maintain pulmonary microvascular stability in adult animals and humans remain largely unexplored.
Does recombinant VEGF-D improve lung vascular integrity and reduce inflammation in preclinical models of acute lung injury?
Does recombinant VEGF-D improve lung vascular integrity and reduce inflammation in preclinical models of acute lung injury?
VEGF-D demonstrates a protective role in promoting lung endothelial barrier integrity and reducing inflammation in acute lung injury via VEGFR2-dependent signaling.
BACKGROUND: Disorders in pulmonary vascular integrity are a prominent feature in many lung diseases. Paracrine signaling is highly enriched in the lung and plays a crucial role in regulating vascular homeostasis. However, the specific local cell-cell crosstalk signals that maintain pulmonary microvascular stability in adult animals and humans remain largely unexplored. METHODS: In this study, we used single-cell RNA-sequencing–based computational pipelines to systematically profile ligand-receptor interactions within the lung microvascular niche and identified VEGF-D (vascular endothelial growth factor-D) as a key local factor with previously unrecognized barrier-protective properties in models of acute lung injury. RESULTS: Our single-cell RNA-sequencing data revealed that, under physiological conditions, soluble ligand-receptor interactions between mesenchymal cells, in particular alveolar fibroblasts, and microvascular endothelial cells are predominantly associated with pathways involved in maintaining vascular integrity as compared with all other cells. On treatment with top identified ligands, we found that VEGF-D significantly enhanced endothelial barrier function and conferred protection against inflammatory challenges induced by TNF-α (tumor necrosis factor-α), IL (interleukin)-1β, and thrombin. This barrier-protective effect of VEGF-D was significantly attenuated by inhibition of VEGFR2 (vascular endothelial growth factor receptor 2), either through small interfering RNA (siRNA) knockdown or pharmacological blockade using specific VEGFR2 inhibitors. Intravenous administration of recombinant VEGF-D in lipopolysaccharide-induced acute lung injury models significantly reduced vascular permeability (7339±2510 arbitrary unit [a.u.] [lipopolysaccharides] versus 5350±1821 a.u. [lipopolysaccharides+VEGF-D]; P <0.05), immune cell infiltration (0.791±0.199×10 6 whole blood cells/mL [lipopolysaccharides] versus 0.540±0.190×10 6 whole blood cells/mL [lipopolysaccharide+VEGF-D]; P <0.01), and the expression of proinflammatory markers TNF-α, IL-6, and keratinocyte chemoattractant in the lung tissue. This effect was abolished in VEGFR2 iECKO (VEGFR2 inducible endothelial cells knockout) mice, confirming that VEGF-D mediates its effects via VEGFR2-dependent signaling. CONCLUSIONS: This study demonstrates an unexpected protective role for VEGF-D in promoting lung endothelial barrier integrity and suggests that paracrine signaling from the alveolar fibroblast niche contributes critically to lung capillary homeostasis.
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2026) studied Acute lung injury. VEGF-D (vascular endothelial growth factor-D) vs. Lipopolysaccharides alone was evaluated on Vascular permeability (p=<0.05). Intravenous administration of recombinant VEGF-D significantly reduced vascular permeability (5350 vs 7339 a.u.; P<0.05) in lipopolysaccharide-induced acute lung injury models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: